Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Metabolic |
| Evidence grade | A Human trial evidence |
| Regulatory status | FDA-approved |
| Human amounts | FDA labelDosing reference Study durations |
| Format | Lyophilized vial |
| Type | Single compound |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4,813 g/mol |
| CAS number | Not listed |
| Sequence | Not listed |
| References | 8 |
| Summary | Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors and is approved by the FDA for type 2 diabetes (Mounjaro), and for chronic weight management and obstructive sleep apnea in adults with obesity (Zepbound). Randomized phase 3 trials have studied its effects on glycemic control, body weight and sleep apnea severity, with gastrointestinal events the most commonly reported adverse reactions. This entry summarizes the FDA labels and published trials for research reference only. |